Shifts in FDA Thinking: What a Single‑Trial Pathway Could Mean for Drug Development

The recent NEJM commentary from Drs. Marty Makary and Vinay Prasad hints at a potential shift in FDA expectations – stating that a single well‑designed pivotal trials is now the default position for US approval ending the widely held doctrine that two pivotal trials are generally required.